Newswise — BREA, CALIF. — (August 2, 2016) — Today at the 68th AACC Annual Scientific Meeting and Clinical Lab Expo, Beckman Coulter, a global leader in the clinical diagnostic industry, introduces the Beckman Coulter Diagnostics Difference―a unique integrated solution that focuses on achieving laboratory excellence by optimizing operational efficiency and clinical effectiveness. The Beckman Coulter Diagnostics Difference is a synergistic, scalable combination of tools, insights, management systems and process improvements designed to enable healthcare enterprises of every size to manage a range of testing volumes and achieve fast, consistent turnaround times (TAT) at peak workloads. Showcased at booth #2600, these comprehensive solutions target a number of diagnostic disciplines, including laboratory automation, chemistry, immunoassay, hematology, urinalysis and microbiology. In addition, Beckman Coulter offers attendees a preview of products in development, such as a new low-volume hematology analyzer* and a medium-volume chemistry platform**.

“Laboratory test results are among today’s greatest influencers of patient-care decisions,” said Arnd Kaldowski, president, Beckman Coulter Diagnostics. “Because we know that successful healthcare organizations rely on laboratory excellence, we are driven to empower clinical laboratory professionals to meet their quality metrics and financial goals through innovative technology and our unwavering commitment to continuous improvement. This is evident in the Beckman Coulter Diagnostics Difference, which includes personalized expert attention, clinical data management tools, and the Danaher Business System – or DBS – philosophy, which is an integrated set of values and processes designed to yield the highest impact for performance and sustained success.”

“Our clinical laboratory customers tell us that standardizing processes to increase capacity, minimize errors and reduce TATs is critical to their success. They are actively seeking a partner to help them achieve this goal,” said John Nosenzo, SVP global customer operations, Beckman Coulter Diagnostics. “The DBS approach enables us to partner with diagnostic laboratories and their interdisciplinary healthcare associates to build and sustain a culture of continuous improvement across all aspects of patient care.”

In addition to its display of products and services, Beckman Coulter is sponsoring a number of clinically focused workshops, a short course, roundtables, and poster presentations that include best practices and the newest advancements in laboratory technology from industry experts. Additional information can be found on

Industry-Sponsored Workshops:Achieving Laboratory Excellence: Debating Winning Strategies for the Clinical Laboratory in the Current Healthcare Environment7:00 a.m. to 9:00 a.m. │ Wednesday, August 3Philadelphia Marriott Downtown, Grand Ballroom ─ Salon D

Moderated by Robert Michel, publisher and editor-in-chief of The Dark Report, clinical experts debate and share ideas about tactical steps laboratories can take to build their clinical and economic contributions in different patient-care settings.

Panelists: Elliot Crouser, M.D. Associate Professor, Division of Pulmonary, Allergy, Critical Care & Sleep Medicine, The Ohio State University Wexner Medical Center

E. David Crawford, M.D., Professor of Surgery/Urology/Radiation Oncology, University of Colorado, Denver

Steven H. Wong, Ph.D., DABCC (TC), FACB, Professor of Pathology and Director, Clinical Chemistry and Toxicology, Wake Forest University School of Medicine

Short Course:1:30 p.m. to 4:00 p.m. │ Sunday, July 31Troubleshooting Clinical Laboratory Errors: Collaborative Case Studies Dr. Jack Zakowski, Beckman Coulter; Dr. Geoff Baird, University of Washington, Seattle; Dr. Sol Green, BD Preanalytic Systems

Roundtables:12:30 p.m. to 1:30 p.m. │ Tuesday, August 2Hepatitis C Virus: Epidemiology, Testing and Management of Adult PatientsAnnette Adelmann, Beckman Coulter

7:30 a.m. to 8:30 a.m. │ Wednesday, August 3Evolving Use of Cardiac Troponins in the ED ― Early Rule-In/Rule-Out Protocols and the Use of Significant DeltasMargot LeClair, Beckman Coulter

Posters: 9:30 a.m. to 5:00 p.m. │ Tuesday or Wednesday, August 2 – 3 Authors will be available at posters from 12:30 p.m. to 1:30 p.m. for discussion with attendees.

Quantitative Detection of CMV, HBV, HCV and HIV-1 on the Beckman Coulter DxN VERIS System*** (B-076) Workflow Characteristics of the Beckman Coulter DxN VERIS Molecular Diagnostics System*** Compared Against Four Automated Laboratory Instruments (B-078)

Access® Estradiol Sensitive Immunoassay****: Performance of a New Sensitive and Accurate Automated Assay (A-199)

Evaluation of Access TSH (3rd IS) Assay***** with Comparison to Multiple Platforms (A-228)

Commutability – Is it Important and Can Patient Samples be Non-Commutable? Use of CLSI EP14-A3 (A-249)

Beckman Coulter DxN VERIS Molecular Diagnostics System*** Sample-to-Sample Crossover Contamination Study (B-074)

An Evaluation of the Analytical Performance of the New Beckman Coulter DxC 700 AU Clinical Chemistry System** (B-356)

Enabling Random Access Molecular Testing*** Using Multiple PCR Cells (B-077)

Reliability Proof of the Beckman Coulter DxH 500 System* (A-281)

Multicenter Evaluation Supports Accuracy of the Beckman Coulter Gram-Negative Identification Product with Improved Database for Clinically Significant Bacteria (A-101)

Multicenter Evaluation of Clindamycin MIC Results for Staphylococci Using MicroScan Dried Gram Positive MIC Panels (A-102)

Multicenter Evaluation of Vancomycin MIC Results at 18 Hours for Staphylococci and Enterococci Using MicroScan Dried Overnight Performance Evaluation Device Panel (A-103)

* Pending submission and clearance by the United States Food and Drug Administration; not yet available for in vitro diagnostic use in the United States.

**Product in development. Pending clearance by the United States Food and Drug Administration and achievement of CE compliance. Not currently available for in vitro diagnostic use.

***Not for sale or distribution in the United States; not available in all markets.

****Access Estradiol Sensitive Immunoassay is still in development.

*****Access® TSH (3rd IS) is CE-marked and pending FDA approval. 

About Beckman CoulterFor 80 years, Beckman Coulter has been the partner of choice for laboratory professionals. Beckman Coulter Diagnostics is dedicated to helping healthcare professionals deliver better patient care, improved quality and lower costs by giving them accurate diagnostic information. The company delivers a comprehensive portfolio of high quality, connected, diagnostic solutions. The combination of our scalable instrument portfolio with our automated and integrated data management systems and broad assay menu allows customers to achieve productivity throughout their organizations and improve patient care. Supporting clinicians’ and physicians’ goal of delivering excellent patient care is at the heart of all we do. Beckman Coulter is, and always has been, singularly devoted to advancing healthcare for every person. For more information, visit

Beckman Coulter, the stylized logo and the Beckman Coulter product and service names mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.# # #